---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-008177"
form_type: "8-K"
ticker: "ECOR"
cik: "0001560258"
company_name: "electroCore, Inc."
filed_at: "2025-05-02T23:59:59+00:00"
generated_at: "2026-05-22T22:42:36.547407+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# electroCore completes acquisition of NeuroMetrix; $4.49/share plus CVRs

## Summary
- Cash consideration of $4.49 per NURO share; each share also gets one CVR tied to Quell sales milestones.
- CVR payments include 8% of Quell Net Sales up to $500K in first year, 6% in second year, plus DPNCheck proceeds.
- electroCore gains Quell Fibromyalgia Solution, expects to leverage VA Hospital System distribution channel.
- NURO shares to be de-listed from Nasdaq Capital Market before trading on May 2, 2025.
- Transaction approved by NURO stockholders on March 21, 2025; closed May 1, 2025.

## SEC filing metadata
- accession: 0001641172-25-008177
- form_type: 8-K
- ticker: ECOR
- cik: 0001560258
- company_name: electroCore, Inc.
- filed_at: 2025-05-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1560258/000164117225008177/0001641172-25-008177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1560258/000164117225008177/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-008177
- JSON: https://secwatch.observer/filing/0001641172-25-008177.json
- Plain text: https://secwatch.observer/filing/0001641172-25-008177.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.